Ensifentrine Drug Asset Due Diligence Report 2026

This Ensifentrine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Ensifentrine can convert its Small molecule drug profile and PDE3 x PDE4 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Ensifentrine (query alias: Ensifentrine)
Modality / target	Small molecule drug; PDE3 x PDE4; PDE3 inhibitors, PDE4 inhibitors
Highest global status	Approved
Originator	Verona Pharma Ltd.
Active developers	Verona Pharma, Inc., Ligand UK Ltd., Nuance Pharma

The MCP disease footprint includes Pulmonary Disease, Chronic Obstructive, Non-cystic fibrosis bronchiectasis, Asthma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06460493	Phase 3	Completed	20	The Proportion of CAT Score Responders in the Full Analysis Set at Week 12
NCT07016412	Phase 2	Recruiting	480	Change from baseline in average forced expiry volume in 1 second (FEV1) area under the curve versus time, from time 0 to 4 hours (AUC0-4h)
NCT06559150	Phase 2	Recruiting	284	Rate of protocol-defined pulmonary exacerbations (number of events per subject-year)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Efficacy and Safety of Ensifentrine in Chinese Participants With COPD

Phase 3; n=525; evaluation: Positive. Reported fields: FEV1 AUC0-12h = 110.0 mL

Ensifentrine Added on to Dual Bronchodilator or Triple Therapy Demonstrates Clinically Meaningful Improvement in CAT Score in Symptomatic Patients with Chronic Obstructive Pulmonary Disease

Phase 3; n=18; evaluation: Positive. Reported fields: CAT(≥2 units at week 12) = 67.0 % ( 38.0 - 100.0)

Ensifentrine in COPD patients taking long-acting bronchodilators: A pooled post-hoc analysis of the ENHANCE-1/2 studies

Phase 3; n=not disclosed; evaluation: Positive. Reported fields: FEV1 AUC0-12 h = 92 mL ( 54 - 131); FEV1 AUC0-12 h = 92 mL ( 54 - 131); FEV1 AUC0-12 h = 74 mL ( 27 - 121)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Ensifentrine addresses Pulmonary Disease, Chronic Obstructive, Non-cystic fibrosis bronchiectasis, Asthma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-07-09	Merck Completes Acquisition of Verona Pharma	Approved	US$10,000.0M stated total
2021-06-09	Nuance Pharma will develop and market Verona's ensifentrine in mainland China, Taiwan, Hong Kong, and Macau.	Phase 3	US$40.0M upfront; US$179.0M milestones; US$219.0M stated total
	Ligand Announces the Close of its Acquisition of Vernalis	Phase 1	US$42.3M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “An improved process for the preparation of ensifentrine and its purification thereof”. The milestone feed surfaced a patent-application signal described as “An improved process for the preparation of ensifentrine”. The milestone feed surfaced a patent-application signal described as “An improved process for the preparation of ensifentrine”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO